A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1422 views | HTML 2213 views | ?
Bianca Schuhmacher1, Benjamin Rengstl1, Claudia Döring1, Julia Bein1, Sebastian Newrzela1, Uta Brunnberg2, Hans Michael Kvasnicka1, Martine Vornanen3, Ralf Küppers4, Martin-Leo Hansmann1, Sylvia Hartmann1
1Dr. Senckenberg Institute of Pathology, Goethe University, Frankfurt am Main, Germany
2Department of Internal Medicine 2, Hospital of the J. W. Goethe University, Frankfurt am Main, Germany
3Department of Pathology, Tampere University Hospital and University of Tampere, Tampere, Finland
4Institute of Cell Biology (Cancer Research), Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
Sylvia Hartmann, email: [email protected]
Keywords: nodular lymphocyte predominant Hodgkin lymphoma, diffuse large B cell lymphoma, T cell/histiocyte rich large B cell lymphoma, host response, gene expression profiling
Received: July 22, 2016 Accepted: September 19, 2016 Published: September 30, 2016
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior. Mechanisms involved in the reduced tumor cell proliferation included a downregulation of MYC and its target genes. Lack of MYC expression was also confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 was upregulated in DEV tumor cells after coculture with T cells or monocytes and its expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new insights into the pathogenesis of LP-DLBCL and an explanation for the relatively low tumor cell content. Moreover, the findings suggest that treatment of these patients with immune checkpoint inhibitors may enhance an already ongoing host response in these patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.